SecBot SecBot
SECBOTREPLAY Home › Report › SANA

SANA · Sana Biotechnology reported Q4 and full-year 2025 financial results…

Sana Biotechnology, Inc · PRESS-RELEASE filed Mar 3, 2026 at 16:05 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 3, 2026 at 16:05 ET

Sana Biotechnology reported Q4 and full-year 2025 financial results alongside significant clinical and operational progress, including 12-month data from its UP421 type 1 diabetes study showing survival and function of hypoimmune-modified islet cells without immunosuppression, publication in NEJM, advancement of SC451 and SG293 programs toward clinical trials, and a strengthened cash position of $138.4 million providing runway into late 2026 following $133.7 million in equity raises.

  • 12-month clinical data from UP421 study show hypoimmune-modified islet cells survive, function, and evade immune detection without immunosuppression in a type 1 diabetes patient
  • NEJM published 12-week results and an accompanying editorial, validating scientific significance
  • SC451 (iPSC-derived hypoimmune islet therapy) on track for IND filing and Phase 1 start as early as 2026
  • SG293 (in vivo CAR-T fusosome) expected to generate first-in-human data in blood cancers in 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access